Clinical trials: Mesothelioma
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
The purpose of this study it to determine the safety and maximally tolerated dose (MTD) of cisplatin administered in the operating room and put into the chest and abdomen for one hour.
- Trial name
- NCT00165555
- Testing
- Cisplatin, Sodium Thiosulfate
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Dana-Farber Cancer Institute
Mesothelioma
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.
- Trial name
- MAPS (NCT00651456)
- Testing
- Standard Chemotherapy (Pemetrexed and Cisplatin), Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
- Where
- 81 sites in France
- Volunteers
- 448 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Mesothelioma
Studying the Clinical Trial Experiences of Patients With Mesothelioma
Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical study may make it more difficult for patients to take part or see it…
- Trial name
- NCT05819580
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer.
- Trial name
- NCT02784171
- Testing
- Cisplatin, Pemetrexed, Pembrolizumab
- Where
- 57 sites in Canada, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Canadian Cancer Trials Group
Mesothelioma
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
Background: Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin. However, the benefits of this treatment are limited, and in most treated patients the disease continues to worsen.
- Trial name
- NCT01445392
- Testing
- Multicycle SS1P, Pemetrexed, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Mesothelioma
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Combining photodynamic therapy with surgery may be an effective treatment for malignant mesothelioma.
- Trial name
- NCT00054002
- Testing
- adjuvant therapy, conventional surgery, porfimer sodium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Mesothelioma
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
- Trial name
- NCT00634205
- Testing
- Valproate plus doxorubicin
- Where
- 8 sites in Belgium, France
- Volunteers
- 45 people
- Sponsor
- European Lung Cancer Working Party
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Malignant Pleural Mesothelioma
Short Neoadjuvant Hemithoracic IMRT for MPM
Malignant pleural mesotheliomas (MPMs) are tumours associated with asbestos exposure involving the tissue lining surrounding the lung.
- Trial name
- NCT00797719
- Testing
- Pre-op RT +/- chemotherapy
- Where
- Canada
- Volunteers
- 104 people
- Sponsor
- University Health Network, Toronto
Pleural Mesothelioma
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung).
- Trial name
- NCT02414945
- Testing
- Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Lung Cancer, Mesothelioma
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
The goal of this clinical research study is to find the highest tolerable dose of radiation that can be given to directly to the pleura (the outer lining of the lungs) using intensity modulated radiation therapy (IMRT) in…
- Trial name
- NCT01134146
- Testing
- IMRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Advanced Malignant Pleural Mesothelioma
Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare disease, but with a very high mortality. MPM is frequently found in advanced stages.
- Trial name
- NCT01869023
- Testing
- Gemcitabine, Cisplatin
- Where
- Mexico
- Volunteers
- 26 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Glioblastoma, Renal Cell Carcinoma
Dendritic Cell Vaccination for Patients with Solid Tumors
The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) - engineered to express the WT1 protein - in patients with limited spread…
- Conditions
- Glioblastoma, Renal Cell Carcinoma, Sarcomas, Breast Cancers
- Trial name
- NCT01291420
- Testing
- autologous dendritic cell vaccination
- Where
- Belgium
- Volunteers
- 48 people
- Sponsor
- University Hospital, Antwerp
Pleural Mesothelioma, Asbestos Exposure
Mesothelioma Early Detection by VOCs
This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma.
- Conditions
- Pleural Mesothelioma, Asbestos Exposure, Pleural Plaque
- Trial name
- MED-VOC (NCT04106973)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Henry Ford Health System
Mesothelioma, Malignant Pleural
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS
Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated to asbestos exposure, still lacking effective therapies.
- Trial name
- MAGNETS (NCT06886672)
- Where
- 2 sites in Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma.
- Trial name
- NCT05647265
- Testing
- Nivolumab, Ipilimumab, Surgical Procedure
- Where
- 132 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma, Advanced
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.
- Trial name
- NCT03213301
- Testing
- Lurbinectedin
- Where
- 8 sites in Italy, Switzerland
- Volunteers
- 42 people
- Sponsor
- Swiss Cancer Institute